FOXP1 and cancer: Compared with non‐cancer controls, FOXP1 protein expression was increased in skeletal muscle of cancer patients defined as cachectic based on body mass loss of >5% in combination with muscle depletion (i.e. low skeletal muscle index) (Figure10A–B).